7
Jun
2022
Rethinking Biotech Manufacturing: Rahul Singhvi on The Long Run
Today’s guest on The Long Run is Rahul Singhvi. Rahul is the co-founder and CEO of Resilience. The company made a splash in the fall of 2020, when it debuted with an $800 million Series A financing. Bob Nelsen of ARCH Venture Partners led the deal. The company has now raised a couple more rounds that add up to more... Read More
7
Jun
2022
Lessons from the Road: What I Learned from Remix’s Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jun
2022
Out in the Community in 2022
TR subscribers: I’m traveling more, and looking forward to seeing more of you in person. I’ll be at the BIO Convention in San Diego, June 13-15. They have plenty of outdoor patio space overlooking the ocean at the San Diego Convention Center. Let’s chat. While at BIO meeting people and gathering ideas, I’m also moderating a panel on improving diversity,... Read More
2
Jun
2022
Startup Profiles: Upstream Gets $200m for Asthma Antibody; Transition Fetches $50m for Condensate Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
May
2022
Managing Through a Hard Time Like No Other
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
May
2022
Seeking Wellness Through More Data, Less Technology, and Better Habits
It only took a pandemic, but well-being has at last emphatically arrived in the corporate world. Before the pandemic, wellness was often viewed as just another item on the HR benefit menu. Some companies offered limited reimbursement for fitness classes, or subsidized access to select health and wellness apps. But in the turbulent wake of COVID-19, well-being is increasingly viewed... Read More
23
May
2022
Building a New Type of Drug Discovery Engine: Chris Gibson on The Long Run
Today’s guest on The Long Run is Chris Gibson. Chris the co-founder and CEO of Salt Lake City-based Recursion. The company was founded in 2013 when Chris was working in the lab of Dean Li at the University of Utah. The idea at Recursion is to do what it calls “industrialized drug discovery.” It combines some of the common tools... Read More
23
May
2022
Sachi Bioworks: Out of the University, Into Outer Space
When they started their first venture together, Dr. Anushree Chatterjee and Dr. Prashant Nagpal were both leading research labs at the University of Colorado, Boulder. Prashant’s lab focused on nanotechnology and molecular biology: Anushree’s focused on building antibiotics for drug-resistant bacteria. That startup, Praan Biosciences, was founded in 2014 to develop improved genetic sequencing technology. Anushree and Prashant had one... Read More
19
May
2022
A Path Forward for More Biotech Workers
Biotech needs more workers. More people who don’t have PhDs and MDs. The industry is 40 years old, and maturing. More companies are developing commercial products. Someone needs to make these products with precision, and at scale. Given the sophisticated nature of the products (cell therapy, gene therapy, advanced biologics, RNA medicines), the fragile global supply chains, and the importance... Read More
17
May
2022
Remix Gets $70m for Small Molecules to Alter RNA Processing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
May
2022
Changing the Balance of Power
Early in my career as a physician, I took care of a woman who died from complications of an abortion procedure. The patient had traveled to the blue state where I practiced, from a red state where she lived that restricted abortion access, to obtain care she couldn’t find or afford at home. She had previously gotten a procedure performed... Read More
11
May
2022
The Limits of Biomedical Innovation, and Why We Should Embrace Them
Last October, I wrote for this publication about the emergence of Antibody-Drug Conjugates (ADCs) for cancer, based on my father’s experience being treated with Padcev for bladder cancer. A few months later, I posted on Twitter that, while Padcev had stopped working for my father, he had since started on another ADC called Trodelvy. His tumors had shrunk. He was... Read More
10
May
2022
MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
May
2022
Fighting Cancer With Food and Drugs: Lew Cantley and Sid Mukherjee on The Long Run
Today’s guests on The Long Run are Lewis Cantley and Siddhartha Mukherjee. They are co-founders of San Francisco-based Faeth Therapeutics. Cantley, who recently moved to Dana Farber Cancer Institute, is a scientist well-known for his work on cancer metabolism. He discovered the PI3kinase pathway that’s an important regulator of normal cell growth, proliferation, metabolism – and which can become activated... Read More
5
May
2022
An Old Idea Whose Time Has Come
People are returning to the office. Many are rethinking the basics of work. So many people are exhausted and anxious. Biotech leaders are thinking carefully about how to proceed. An R&D-based industry needs people in environments that allow them to be energized, creative, collaborative. Here’s one simple idea: Walking meetings. The “walk and talk” business meeting isn’t new. But we... Read More
3
May
2022
Dianthus Gets $100m to Take Complement Inhibition to a New Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
May
2022
Ram Aiyar on Finding Deal Alignment Internally and Externally
Ram Aiyar is currently the CEO of Cambridge, Mass.-based Korro Bio, a company using RNA editing to treat genetic diseases, including Alpha-1 Antitrypsin Deficiency. Before he took that job, he was a founder and executive vice president of corporate and business development at Corvidia Therapeutics. That company was acquired by Novo Nordisk in August 2020 for $725 million upfront, and... Read More
2
May
2022
Biopharmas: Digitizing, But Not Quite Digital
What a difference two years makes. In January 2020, I left my role as a senior partner at a corporate life-science venture fund to pursue my interest in what I recognized as a captivating frontier: the intersection of biopharma with emerging digital and data technology. I set up an independent consultancy, and advised senior R&D executives in both large and... Read More
28
Apr
2022
A Big Opportunity in Obesity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2022
The Timmerman Traverse for Life Science Cares Is Back, Fighting Poverty
The biotech community has plenty of people willing to work to support vulnerable members of our society. This year, I’m doing what I can to again mobilize the biotech community to fight poverty. I’m happy to announce the Timmerman Traverse for Life Science Cares. It’s a Presidential Traverse hike set for Sept. 11-14, 2022. This expedition builds on the success... Read More